CRSP - What's Going On With Crispr Therapeutics Stock Monday? | Benzinga
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Monday on what appears to be continued momentum from the recent regulatory authorization of the company's CRISPR/Cas9 gene-edited therapy.
What Happened: Last week, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for CASGEVY, a CRISPR/Cas9 gene-edited therapy for the treatment of sickle cell disease.
The therapy was authorized for ...